SK2562001A3 - The use of carbamates and urea compositions for effecting a neuronal activity and pharmaceutical compositions containing them - Google Patents

The use of carbamates and urea compositions for effecting a neuronal activity and pharmaceutical compositions containing them Download PDF

Info

Publication number
SK2562001A3
SK2562001A3 SK256-2001A SK2562001A SK2562001A3 SK 2562001 A3 SK2562001 A3 SK 2562001A3 SK 2562001 A SK2562001 A SK 2562001A SK 2562001 A3 SK2562001 A3 SK 2562001A3
Authority
SK
Slovakia
Prior art keywords
group
straight
branched chain
branched
pyridyl
Prior art date
Application number
SK256-2001A
Other languages
English (en)
Slovak (sk)
Inventor
Jia-He Li
Joseph P Steiner
Gregory S Hamilton
Original Assignee
Guilford Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guilford Pharm Inc filed Critical Guilford Pharm Inc
Publication of SK2562001A3 publication Critical patent/SK2562001A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
SK256-2001A 1998-08-25 1999-08-24 The use of carbamates and urea compositions for effecting a neuronal activity and pharmaceutical compositions containing them SK2562001A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/139,672 US6242468B1 (en) 1997-02-27 1998-08-25 Carbamate and urea compositions and neurotrophic uses
PCT/US1999/019261 WO2000010553A2 (en) 1998-08-25 1999-08-24 Carbamate and urea compositions and neurotrophic uses

Publications (1)

Publication Number Publication Date
SK2562001A3 true SK2562001A3 (en) 2001-09-11

Family

ID=22487769

Family Applications (1)

Application Number Title Priority Date Filing Date
SK256-2001A SK2562001A3 (en) 1998-08-25 1999-08-24 The use of carbamates and urea compositions for effecting a neuronal activity and pharmaceutical compositions containing them

Country Status (18)

Country Link
US (1) US6242468B1 (hu)
EP (1) EP1107757A2 (hu)
JP (1) JP2002523367A (hu)
KR (1) KR20010072992A (hu)
CN (1) CN1313767A (hu)
AU (1) AU5687999A (hu)
BG (1) BG105340A (hu)
BR (1) BR9912988A (hu)
CA (1) CA2341530A1 (hu)
CZ (1) CZ2001274A3 (hu)
EA (1) EA200100271A1 (hu)
HU (1) HUP0103166A3 (hu)
IL (1) IL140958A0 (hu)
MX (1) MXPA01001937A (hu)
NO (1) NO20010946D0 (hu)
PL (1) PL346759A1 (hu)
SK (1) SK2562001A3 (hu)
WO (1) WO2000010553A2 (hu)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008960B1 (en) 1999-03-02 2006-03-07 Vitreo-Retinal Technologies, Inc. Agents for intravitreal administration to treat or prevent disorders of the eye
EP1196386A2 (en) * 1999-07-06 2002-04-17 Vertex Pharmaceuticals Incorporated N-substituted glycine derivatives
US20030199574A1 (en) * 2000-03-02 2003-10-23 Vitreo-Retinal Technologies, Inc. Treatment of ophthalmic disorders using urea and urea derivatives
US7977385B2 (en) * 2000-03-02 2011-07-12 Numoda Biotechnologies, Inc. Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
US20050137124A1 (en) * 2002-08-09 2005-06-23 Vitreo-Retinal Technologies, Inc. A California Corporation Agents for intravitreal administration to treat or prevent disorders of the eye
EP1402888A1 (en) * 2002-09-18 2004-03-31 Jerini AG The use of substituted carbocyclic compounds as rotamases inhibitors
EP1720548A1 (en) * 2004-03-02 2006-11-15 Wyeth Non-immunosuppressive immunophilin ligands as neuroprotective and/or neuroregenerative agents
EP1720886A1 (en) 2004-03-02 2006-11-15 Wyeth Macrolides and methods for producing same
WO2007061554A2 (en) * 2005-10-21 2007-05-31 Purdue Research Foundation Dosage of 4-aminopyridine derivatives for treatment of central nervous system injuries
CN104870421A (zh) * 2011-12-27 2015-08-26 比皮艾思药物研发有限公司 用于预防或治疗als的苯基氨基甲酸酯化合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214034A (en) 1986-09-26 1993-05-25 Mitsui Toatsu Chemicals, Incorporated Catechol derivatives, and preventive and remedial preparations for regressive disorders in the central nervous system containing the same
FI874163A (fi) 1986-09-26 1988-03-27 Mitsui Toatsu Chemicals Katekolderivat samt preparat innehaollande desamma foer haemmande och botande av regressiva sjukdomar i det centrala nervsystemet.
IT1206078B (it) 1987-06-03 1989-04-14 Polifarma Spa Procedimento per la produzione di acido 3-indolpiruvico e suoi derivati loro uso farmaceutico
US5232923A (en) 1988-03-18 1993-08-03 Mitsui Toatsu Chemicals, Incorporated Catechol derivatives and pharmaceutical preparations containing same
US5166317A (en) 1988-10-31 1992-11-24 Houston Biotechnology Incorporated Neurotrophic factor
US5215969A (en) 1989-08-11 1993-06-01 Hahnemann University Dopaminergic neurotrophic factor for treatment of Parkinson's disease
US5620971A (en) 1991-05-09 1997-04-15 Vertex Pharmaceuticals Incorporated Biologically active acylated amino acid derivatives
US5744485A (en) 1994-03-25 1998-04-28 Vertex Pharmaceuticals Incorporated Carbamates and ureas as modifiers of multi-drug resistance
IL115685A (en) * 1994-11-16 2000-08-31 Vertex Pharma Amino acid derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
US6037370A (en) 1995-06-08 2000-03-14 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5717092A (en) 1996-03-29 1998-02-10 Vertex Pharmaceuticals Inc. Compounds with improved multi-drug resistance activity
US5780484A (en) 1996-11-13 1998-07-14 Vertex Pharmaceuticals Incorporated Methods for stimulating neurite growth with piperidine compounds
US5840736A (en) 1996-11-13 1998-11-24 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5811434A (en) 1996-11-13 1998-09-22 Vertex Pharmacueticals Incorporated Methods and compositions for stimulating neurite growth
US5935989A (en) * 1996-12-31 1999-08-10 Gpi Nil Holdings Inc. N-linked ureas and carbamates of heterocyclic thioesters
ZA98825B (en) * 1997-02-27 1998-10-19 Guilford Pharm Inc Method of using neurotrophic carbamates and ureas

Also Published As

Publication number Publication date
MXPA01001937A (es) 2002-04-24
CN1313767A (zh) 2001-09-19
EP1107757A2 (en) 2001-06-20
KR20010072992A (ko) 2001-07-31
BG105340A (en) 2001-12-29
WO2000010553A3 (en) 2000-05-18
NO20010946L (no) 2001-02-23
CA2341530A1 (en) 2000-03-02
US6242468B1 (en) 2001-06-05
PL346759A1 (en) 2002-02-25
BR9912988A (pt) 2001-10-02
WO2000010553A2 (en) 2000-03-02
JP2002523367A (ja) 2002-07-30
EA200100271A1 (ru) 2001-10-22
HUP0103166A3 (en) 2002-10-28
IL140958A0 (en) 2002-02-10
NO20010946D0 (no) 2001-02-23
HUP0103166A2 (hu) 2002-05-29
AU5687999A (en) 2000-03-14
CZ2001274A3 (cs) 2001-09-12

Similar Documents

Publication Publication Date Title
US5721256A (en) Method of using neurotrophic sulfonamide compounds
US6200972B1 (en) Heterocyclic esters and amides
US5874449A (en) N-linked sulfonamides of heterocyclic thioesters
SK26599A3 (en) Heterocyclic thioesters and ketones
US5935989A (en) N-linked ureas and carbamates of heterocyclic thioesters
SK2562001A3 (en) The use of carbamates and urea compositions for effecting a neuronal activity and pharmaceutical compositions containing them
WO1998037882A1 (en) Method of using neurotrophic carbamates and ureas
US6274607B1 (en) N-linked ureas and carbamates of heterocyclic thioesters
US6294551B1 (en) N-linked sulfonamides of heterocyclic thioesters
US20020013344A1 (en) Rotamas enzyme activity inhibitors
AU713302B2 (en) Rotamase enzyme activity inhibitors
MXPA99007938A (en) Method of using neurotrophic carbamates and ureas
MXPA99007384A (en) Method of using neutrophic sulfonamide compounds
MXPA98003356A (en) Inhibitors of the activity of enzima rotam